Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB1801 versus docetaxel, each with trastuzumab + pertuzumab, as first-line treatment for HER2-positive recurrent or metastatic breast cancer
CTR20253167Phase 2Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Sep 2025
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of albumin-bound docetaxel in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Sep 2025; status: active.
02
Drugs
albumin-bound docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20253167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253167.